Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Vimpat Dry Syrup Now Available: Daiichi Sankyo, UCB
March 12, 2019
- BMS, Ono Submit Additional Study Data on Orencia for Prevention of Structural Damage to Joints
March 12, 2019
- Fujifilm Toyama Chemical, Sanwa Kagaku Tie Up for Lantus Biosimilar Promotion
March 12, 2019
- UCB, Otsuka to End Copromotion Deal for E Keppra in Japan in 2020
March 12, 2019
- Daiichi Sankyo Espha Launches Authorized Iressa Generic, Introducing AI to Respond to Inquiries
March 12, 2019
- Entyvio Shows Superiority to Humira in PIIIb Study for UC: Takeda
March 12, 2019
- Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key
March 11, 2019
- Japan Ethical Drug Sales Up 3.3% in January: Crecon
March 11, 2019
- CMIC CMO, Aprecia Join Hands for 3D Printing Therapies
March 11, 2019
- Eisai CEO Says “20% ROE in 2025” within Reach If All 3 Alzheimer’s Candidates, Lenvima Deliver
March 8, 2019
- Shionogi Bags Japan/Taiwan Rights to Akili’s Digital Medicines for ADHD, Autism
March 8, 2019
- Avastin Top Seller in Japan in February: Encise Snapshot
March 8, 2019
- Mitsubishi Tanabe’s Rupafin Most Promoted Drug in December: Anterio
March 8, 2019
- Eisai Seeks Japan Approval for Insomnia Med Lemborexant
March 8, 2019
- Toa Confident in Ensuring Stable Supply of Symbicort Generic with Expertise in Dry Powder Inhaler Manufacturing
March 8, 2019
- Teva Takeda Discloses Info on Producing Countries of Its Generic APIs
March 7, 2019
- Sawai’s Generic Abilify Approved for Depression
March 7, 2019
- Xofluza Filed in US to Treat Patients at High Risk of Flu-Related Complications: Shionogi
March 7, 2019
- Japan’s 1st Drug to Reduce Alcohol Consumption Launched: Otsuka
March 6, 2019
- Alcon Pharma to Be Integrated into Novartis Japan in April
March 6, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…